<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01335191</url>
  </required_header>
  <id_info>
    <org_study_id>THYMON-11001</org_study_id>
    <nct_id>NCT01335191</nct_id>
  </id_info>
  <brief_title>Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects (THYMON-11001)</brief_title>
  <official_title>Clinical Study of TUTI-16 in Asymptomatic, HIV-1 Infected Subjects Effectively Controlled by Antiretroviral Therapy and the Effects on Viral Load During a Structured Treatment Interruption</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thymon, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thymon, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol represents the third in human study of TUTI-16, and is being conducted to
      gather additional safety and human immunogenicity (anti-HIV-1 Tat titers) data of
      subcutaneously administered TUTI-16.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, HIV-1 infected subjects on ART, with undetectable HIV-1 viral load, will be
      immunized with 1mg TUTI-16 or placebo in a randomized double blind fashion (prime and 3 week
      boost). Three weeks after the 3 week boost (week 6) ART will be stopped. HIV-1 viral load and
      CD4+ T-cell levels will be determined at defined intervals through 54 weeks (48 weeks Post
      ART discontinuation).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-Tat Antibody Titer</measure>
    <time_frame>54 weeks</time_frame>
    <description>ELISA based chemiluminescent assay to determine the anti-Tat antibody response</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>TUTI-16 (1.0 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two subcutaneous injections of 1.0 mg at Day 0 and Week 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two subcutaneous injections of placebo at Day 0 and Week 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TUTI-16 (1.0 mg)</intervention_name>
    <description>Two subcutaneous injections of TUTI-16 (1.0 mg) at Day 0 and Week 3.</description>
    <arm_group_label>TUTI-16 (1.0 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two subcutaneous injections of Placebo at Day 0 and Week 3.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and Females

          -  Age ≥ 18 and ≤ 50 years at Screening

          -  Body weight of 50-100 kg (inclusive) at Screening.

          -  HIV-1 seropositive subjects on effective ART for &gt; 12 months (undetectable HIV plasma
             viremia), viral set point before ART &gt; 10,000.

          -  CD4+ T-cell count ≥ 500/mm3.

          -  No antiviral drug within 8 weeks of screening. Patients stabilized on Aciclovir and
             Valciclovir for more than 6 months may be enrolled.

          -  Karnofsky performance status &gt; 90% at screening.

          -  In good health as determined by medical history, a baseline physical examination,
             vital signs, and clinical laboratory tests.

          -  Subject is willing and able to sign written informed consent prior to beginning study
             procedures.

          -  Subject is willing and able to follow instructions, comply with the protocol
             requirements and make all required study visits.

        Exclusion Criteria:

          -  Females planning to become pregnant during the course of the study.

          -  Females with a positive pregnancy test at Screening or study enrollment.

          -  Any out-of range laboratory value at screening that has not been reviewed, approved
             and documented as not clinically significant by the Principal Investigator.

          -  Systemic infection or other vaccination within 6 weeks prior to screening. Live
             vaccine within 1 year of screening.

          -  Autoimmune disease (e.g., psoriasis, rheumatoid arthritis, etc.) or inflammatory bowel
             disease confirmed by clinical history.

          -  Positive at screen for HBV (by HBsAg assay) or HCV (by antibody ELISA) unless there is
             no active infection as judged by an elevated alanine aminotransferase (ALT) at
             screening.

          -  Alanine aminotransferase (ALT) above the upper limit of normal at screening.

          -  Hemoglobin outside of laboratory normal range at screening.

          -  Absolute neutrophil counts outside of laboratory normal range at screening.

          -  Platelet count outside of laboratory normal range at screening.

          -  A history of significant drug allergy.

          -  A general medical or psychological condition or behavior, including current substance
             dependence or abuse that, in the opinion of the investigator, might not permit the
             subject to complete the study or sign the informed consent.

          -  Subjects experiencing an acute Herpetic event.

          -  Any other condition or clinically significant abnormal findings on the physical
             examination, medical history, or clinical laboratory results during screening that, in
             the opinion of the Principal Investigator would make the subject unsuitable for the
             study or put them at additional risk.

          -  Routine or PRN consumption of immune suppressive medications that the subject is
             unable or unwilling to discontinue during the study.

          -  Inability to understand or follow study instructions.

          -  Participation in another investigational drug/vaccine study within 30 days preceding
             the first injection of investigational agent in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mardik Donikyan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinilabs, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinilabs</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2011</study_first_submitted>
  <study_first_submitted_qc>April 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2011</study_first_posted>
  <results_first_submitted>December 7, 2012</results_first_submitted>
  <results_first_submitted_qc>January 14, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 15, 2013</results_first_posted>
  <last_update_submitted>January 14, 2013</last_update_submitted>
  <last_update_submitted_qc>January 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>vaccine</keyword>
  <keyword>lipopeptide</keyword>
  <keyword>Tat</keyword>
  <keyword>TUTI-16</keyword>
  <keyword>THYMON</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TUTI-16 (1.0 mg)</title>
          <description>Two subcutaneous injections of 1.0 mg at Day 0 and Week 3.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Two subcutaneous injections of placebo at Day 0 and Week 3.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TUTI-16 (1.0 mg)</title>
          <description>Two subcutaneous injections of 1.0 mg at Day 0 and Week 3.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Two subcutaneous injections of placebo at Day 0 and Week 3.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" lower_limit="27" upper_limit="55"/>
                    <measurement group_id="B2" value="43" lower_limit="24" upper_limit="54"/>
                    <measurement group_id="B3" value="43" lower_limit="24" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Anti-Tat Antibody Titer</title>
        <description>ELISA based chemiluminescent assay to determine the anti-Tat antibody response</description>
        <time_frame>54 weeks</time_frame>
        <population>all subjects enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>TUTI-16 (1.0 mg)</title>
            <description>Two subcutaneous injections of 1.0 mg at Day 0 and Week 3.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two subcutaneous injections of placebo at Day 0 and Week 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-Tat Antibody Titer</title>
          <description>ELISA based chemiluminescent assay to determine the anti-Tat antibody response</description>
          <population>all subjects enrolled</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="698" lower_limit="0" upper_limit="3000"/>
                    <measurement group_id="O2" value="4" lower_limit="0" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>TUTI-16 (1.0 mg)</title>
          <description>Two subcutaneous injections of 1.0 mg at Day 0 and Week 3.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Two subcutaneous injections of placebo at Day 0 and Week 3.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>injection site reaction</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Gideon Goldstein</name_or_title>
      <organization>Thymon LLC</organization>
      <phone>(973) 467-9558</phone>
      <email>gidgold@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

